Abstract

ATAGI has provided clinical advice on the use of Nirsevimab (Beyfortus, Sanofi-Aventis) for the prevention of severe disease due to respiratory syncytial virus (RSV) infection in infants. 

  • Recommendation
  • Western Pacific
  • Australia
  • Children
  • RSV (Respiratory syncytial virus)